Bahar Dakiki

Bahar Dakiki

Auto-generated profile, based on publicly available information

Bahar Dakiki

Department of Data Science, Dana Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ASAnil Aktas Samur
Anil Aktas Samur
Jill CorreJill Corre
Jill Corre
STSrikanth Talluri
Srikanth Talluri
PSParth Shah
Parth Shah
AGAntoine Graffeuil
Antoine Graffeuil
MSMehmet Kemal Samur
Mehmet Kemal Samur
PURPOSE: The diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early intervention becomes a priority, the role of genomic features in differentiating risk is gaining attention. METHODS: This study analyzed next-generation sequencing data from 224 precursor condition samples with 51 patients having paired SMM and multiple myeloma (MM) and 1,779 samples from newly diagnosed MM to identify genomic features linked to progression in SMM and those with a low-risk nonprogressor precursor condition. RESULTS: Our findings from paired samples revealed no significant differences in somatic alterations and clonal structures between SMM and MM samples from the same patient. This indicates that plasma cells in progressor SMM are genomically pre-equipped with changes that define myeloma. Over 80% of driver mutations were present at both time points, and more than 66% of progressor samples showed only minor clonal changes. We further compared genomic changes between nonprogressor and progressor SMM. Nonprogressor plasma cells showed significantly lower mutational load and the absence of copy number alterations on chromosome 8. They reduced focal genomic loss compared with progressor plasma cells. A scoring system using genomic features predictively identified patients with low-risk SMM unlikely to progress, validated on 101 additional independent samples, and additive clinical value of genomic classification was further shown in combination with 20/2/20. CONCLUSION: In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance–like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.

18 February 2021 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
BOBirol Ocak
Birol Ocak
FAFatma Öz Atalay
Fatma Öz Atalay
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
MOMine Ozsen
Mine Ozsen
BDBahar Dakiki
Bahar Dakiki
TETürkkan Evrensel
Türkkan Evrensel
Endometrial endometrioid carcinoma (EEC) represents approximately 75–80% of endometrial carcinoma cases. Three hundred thirty-six patients with EEC followed-up in the authors’ medical center between and 2010–2018 were included in our study. Two hundred seventy-two low- and intermediate- EEC patients were identified using the European Society for Medical Oncology criteria and confirmed by histopathological examination. Recurrence was reported in 17 of these patients. The study group consisted of patients with relapse. A control group of 51 patients was formed at a ratio of 3:1 according to age, stage, and grade, similar to that in the study group. Of the 17 patients with recurrent disease, 13 patients (76.5%) were stage 1A, and 4 patients (23.5%) were stage 1B. No significant difference was found in age, stage, and grade between the case and control groups (p>0.05). Body mass index, parity, tumor size, lower uterine segment involvement, SqD, and Ki-67 index with p<0.25 in the univariate logistic regression analysis were included in the multivariate analysis. Ki-67 was statistically significant in multivariate analysis (p=0.018); however, there was no statistical significance in SqD and other parameters. Our data suggest that the Ki-67 index rather than SqD needs to be assessed for recurrence in patients with low- and intermediate-risk EEC.

1 April 2022 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
BOBirol Ocak
Birol Ocak
SSSüreyya Sarihan
Süreyya Sarihan
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
BDBahar Daki̇ki̇
Bahar Daki̇ki̇
BCBurcu Caner
Burcu Caner
TETürkkan Evrensel
Türkkan Evrensel
Background: In non-small cell lung cancer (NSCLC), immunotherapy is a treatment option in patients without targetable mutations in second and later lines. Nevertheless, there is no validated test that can predict immunotherapy response. Material and Methods: Our study aimed to investigate the effect of radiotherapy (RT) on survival in patients with NSCLC receiving immunotherapy after first-line chemotherapy. Twenty-five patients diagnosed with NSCLC and received immunotherapy after at least one previous chemotherapy line were included in our study. Results: The median age of the patients was 61.7 (26.6-81.2) years. 19 (76%) patients were male. 11 (44%) of the patients had received immunotherapy in the second-line and 14 (66%) in ≥3 lines. Patients had received a median of 5 cycles (1-27) of immunotherapy. RT to immunotherapy interval was 6.4 months (1.0-11.8). Partial response was observed in 12 patients, stable disease in 8 patients, progression in 1 patient, and hyperprogression in 4 patients. Median progression-free survival (PFS) was 4.4 months (95% CI; 3.2-5.6), and median overall survival (OS) was 16.4 months (95% CI; 5.6-27.3). 14 (56%) of the patients had received RT. RT was administered to 12 patients before immunotherapy, and two patients received RT to bones during immunotherapy. The patients who received RT had statistically longer PFS (4.9 vs 3.9 months, p=0.012) and OS (18.7 vs 7.3 months, p=0.023) comparing those without RT. Conclusions: Our findings showed that RT significantly improved the survival in patients who received immunotherapy, pointing that RT may have an influential role in immunotherapy response.

1 April 2020 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
BOBirol Ocak
Birol Ocak
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
BDBahar Daki̇ki̇
Bahar Daki̇ki̇
HOHikmet Utku Odman
Hikmet Utku Odman
ADadem deligonul
adem deligonul
TETürkkan Evrensel
Türkkan Evrensel
Ilişkilendirilmiştir. Malign peritoneal mezotelyoma (MPM) plevral tutulumdan sonra ikinci sıklıkta görülür. Çalışmamızda MPM tanısı alan hastalarda demografik özelliklerin, kullanılan tedavi seçeneklerinin incelenmesi amaçlandı. Çalışmamızda 12 erkek, 4 kadın toplamda 16 hastanın medyan yaşı 66 (46-93) yıldı. 15 hasta epiteolid, 1 hasta bifazik histopatolojiye sahipti. 2 hastaya hipertermik intraperitoneal kemoterapi (HİPEK) yapılmıştı. Birinci seçim kemoterapi alan 16 hasta, ikinci seçim kemoterapi alan 13 hasta, üçüncü seçim kemoterapi alan 4 hasta, dördüncü seçim kemoterapi alan 1 hasta mevcuttu. Birinci seçim kemoterapi alan hastaların medyan progresyonsuz sağkalımı 14,4 ay (CI %95 7,4:21,4) saptandı. Hastaların medyan toplam sağkalımı 22,0 aydı (CI %95 16:27,9). Standart tedavi seçenekleri arasında olan sitoredüksiyon cerrahisi + HİPEK, sistemik kemoterapi ve immünoterapinin optimal kullanımı ve bu tedavilere uygun hasta seçimi için prospektif, multidispliner, daha fazla hasta sayısı içeren çalışmalara ihtiyaç vardır.

26 July 2021
Verified
Book
Closed access
PDF file
NKNezih Kavak
Nezih Kavak
AIAysegul Ilhan
Aysegul Ilhan
BABurcu Altındağ Avcı
Burcu Altındağ Avcı
NANilgün Altın
Nilgün Altın
TBTunga Barçın
Tunga Barçın
ABAyben Yentek Balkanay
Ayben Yentek Balkanay
Onkoloji alanındaki tüm dünyanın yakın takip ettiği bilimsel gelişmeler ışığında günümüzde artık sistemik kemoterapi gibi konvansiyonel tedaviler yerlerini büyük ölçüde immünoterapi, moleküler hedefli ilaçlar ve gen tedavilerine bırakmaya başlamıştır.Bu tedavi seçeneklerinin her biri ayrı ayrı vazgeçilmez önemde olup tedavi seçimleri ve sıralamaları bireyselleştirilmiş tedavi stratejilerisayesinde her hastaya özgü bir şekilde planlanmaktadır. Gerek bu tedavi modalitelerinin yan etkileri gerekse hastalığın doğal seyri gereği acil müdahele gerektiren durumların varlığı yadsınamaz. Dolayısıyla çağdaş tedavi modalitelerinin kullanım alanımıza girmesi Onkolojik Acillerin pratiğimizdeki yerini değiştirmemiştir ve Onkoloji pratiğinde hem hastalarımızın hem de bizlerin yönetiminde zaman zaman zorlandığımız bu konulara güncel yaklaşımları alanında uzman ve akademik vizyonu olan hocalarımızın katkılarıyla hazırladık.Emeği geçen hocalarıma teker teker davetimi kırmayıp verdikleri destek için teşekkür ediyorum. Ayrıca Onkoloji alanında yayımladığımız ve yayımlamayı planladığımız kitapların hazırlanmasında emeği geçen ve her an yanımızda olan başta Akademisyen Yayınevi sahibi Yasin DİLMEN olmak üzere tüm yayınevi çalışanlarına da teşekkür ederim.

4 September 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
BOBirol Ocak
Birol Ocak
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
IEIsmail Ertürk
Ismail Ertürk
MKMustafa Korkmaz
Mustafa Korkmaz
DEDilek Erdem
Dilek Erdem
TETürkkan Evrensel
Türkkan Evrensel
Background: This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular endothelial growth factor (VEGF) agent in patients with metastatic clear-cell renal-cell carcinoma (ccRCC). Methods: We included 106 de novo metastatic ccRCC patients who received nivolumab after progression on at least one anti-VEGF agent. Multivariate Cox regression analysis was performed to investigate the factors affecting survival in patients receiving nivolumab. Results: Of the 106 de novo metastatic ccRCC patients, 83 (78.3%) underwent CN. There were no statistical differences between the two groups in terms of age, gender, Eastern Cooperative Oncology Group (ECOG) score, tumor size, International Metastatic RCC Database Consortium (IMDC) risk group, number of previous treatment lines, first-line anti-VEGF therapy, or metastasis sites (p = 0.137, p = 0.608, p = 0.100, p = 0.376, p = 0.185, p = 0.776, p = 0.350, and p = 0.608, respectively). The patients who received nivolumab with CN had a longer time to treatment discontinuation (TTD) [14.5 months, 95% confidence interval (CI): 8.6–20.3] than did those without CN 6.7 months (95% CI: 3.9–9.5) (p = 0.001). The median overall survival (OS) was 22.7 months (95% CI: 16.1–29.4). The patients with CN had a median OS of 22.9 months (95% CI: 16.3–29.4), while those without CN had a median OS of 8.1 months (95% CI: 5.6–10.5) (p = 0.104). In the multivariate analysis, CN [hazard ratio (HR): 0.521; 95% CI: 0.297–0.916; p = 0.024] and the IMDC risk score (p = 0.011) were statistically significant factors affecting TTD; however, the IMDC risk score (p = 0.006) was the only significant factor for overall survival. Conclusions: Our study showed that the TTD of nivolumab was longer in metastatic ccRCC patients who underwent cytoreductive nephrectomy.